Tags

Type your tag names separated by a space and hit enter

Pivmecillinam and adverse birth and neonatal outcomes: a population-based cohort study.
Scand J Infect Dis. 2004; 36(10):733-7.SJ

Abstract

A previous study unexpectedly showed an increased, statistically imprecise, risk of low Apgar score in children of women redeeming prescriptions for pivmecillinam in late pregnancy. To improve statistical precision we extended the previous dataset with data for 5 more y, and in addition added more neonatal outcomes. We thus examined the risk of adverse birth and neonatal outcomes among pregnant users of pivmecillinam based on population-based registries in North Jutland County, Denmark. We included 63,659 women with a live birth, or stillbirth after the 28th week of gestation. 2031 had redeemed prescriptions for pivmecillinam any time during pregnancy, 559 in the first trimester and 371 within 28 d before delivery. Adjusted odds ratios were: birth defects 0.83 (95% confidence interval (95% CI) 0.53-1.32) for exposure during first trimester, preterm delivery 0.96 (95% CI 0.79-1.18) and low birth weight 0.79 (95% CI 0.52-1.20) for exposure any time during pregnancy, and stillbirth 1.19 (95% CI 0.30-4.80), low Apgar score 1.17 (95% CI 0.37-3.66), hypoglycaemia 1.03 (95% CI 0.53-2.00), and respiratory distress syndrome 0.79 (95% CI 0.38-1.68) for exposure within 28 d before delivery. Use of pivmecillinam during pregnancy did not appear to increase the risk of adverse birth and neonatal outcomes; however, statistical precision is still low.

Authors+Show Affiliations

Department of Clinical Epidemiology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark. mvs@soci.au.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15513399

Citation

Vinther Skriver, Mette, et al. "Pivmecillinam and Adverse Birth and Neonatal Outcomes: a Population-based Cohort Study." Scandinavian Journal of Infectious Diseases, vol. 36, no. 10, 2004, pp. 733-7.
Vinther Skriver M, Nørgaard M, Pedersen L, et al. Pivmecillinam and adverse birth and neonatal outcomes: a population-based cohort study. Scand J Infect Dis. 2004;36(10):733-7.
Vinther Skriver, M., Nørgaard, M., Pedersen, L., Carl Schønheyder, H., & Sørensen, H. T. (2004). Pivmecillinam and adverse birth and neonatal outcomes: a population-based cohort study. Scandinavian Journal of Infectious Diseases, 36(10), 733-7.
Vinther Skriver M, et al. Pivmecillinam and Adverse Birth and Neonatal Outcomes: a Population-based Cohort Study. Scand J Infect Dis. 2004;36(10):733-7. PubMed PMID: 15513399.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pivmecillinam and adverse birth and neonatal outcomes: a population-based cohort study. AU - Vinther Skriver,Mette, AU - Nørgaard,Mette, AU - Pedersen,Lars, AU - Carl Schønheyder,Henrik, AU - Sørensen,Henrik Toft, PY - 2004/10/30/pubmed PY - 2004/12/16/medline PY - 2004/10/30/entrez SP - 733 EP - 7 JF - Scandinavian journal of infectious diseases JO - Scand J Infect Dis VL - 36 IS - 10 N2 - A previous study unexpectedly showed an increased, statistically imprecise, risk of low Apgar score in children of women redeeming prescriptions for pivmecillinam in late pregnancy. To improve statistical precision we extended the previous dataset with data for 5 more y, and in addition added more neonatal outcomes. We thus examined the risk of adverse birth and neonatal outcomes among pregnant users of pivmecillinam based on population-based registries in North Jutland County, Denmark. We included 63,659 women with a live birth, or stillbirth after the 28th week of gestation. 2031 had redeemed prescriptions for pivmecillinam any time during pregnancy, 559 in the first trimester and 371 within 28 d before delivery. Adjusted odds ratios were: birth defects 0.83 (95% confidence interval (95% CI) 0.53-1.32) for exposure during first trimester, preterm delivery 0.96 (95% CI 0.79-1.18) and low birth weight 0.79 (95% CI 0.52-1.20) for exposure any time during pregnancy, and stillbirth 1.19 (95% CI 0.30-4.80), low Apgar score 1.17 (95% CI 0.37-3.66), hypoglycaemia 1.03 (95% CI 0.53-2.00), and respiratory distress syndrome 0.79 (95% CI 0.38-1.68) for exposure within 28 d before delivery. Use of pivmecillinam during pregnancy did not appear to increase the risk of adverse birth and neonatal outcomes; however, statistical precision is still low. SN - 0036-5548 UR - https://www.unboundmedicine.com/medline/citation/15513399/Pivmecillinam_and_adverse_birth_and_neonatal_outcomes:_a_population_based_cohort_study_ DB - PRIME DP - Unbound Medicine ER -